We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+8.96%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.08B
AUM Growth
+$407M
Cap. Flow
+$226M
Cap. Flow %
4.45%
Top 10 Hldgs %
23.59%
Holding
154
New
18
Increased
54
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
DOCS icon
Doximity
DOCS
+$69.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$63M
3
MDB icon
MongoDB
MDB
+$59.3M
4
DV icon
DoubleVerify
DV
+$47.6M
5
FLYW icon
Flywire
FLYW
+$39.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$165M
2
DUOL icon
Duolingo
DUOL
+$33.1M
3
KURA icon
Kura Oncology
KURA
+$32.8M
4
COGT icon
Cogent Biosciences
COGT
+$30.6M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 38.81%
2 Technology 24%
3 Industrials 15.64%
4 Consumer Discretionary 5.21%
5 Utilities 4.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DICE
151
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-1,370,261
Closed -$20.8M
CCXI
152
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-728,385
Closed -$18M
BHVN
153
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-1,129,100
Closed -$165M
3 4 5 6
7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Eventide Asset Management held 154 positions worth $5.08B, up 8.7% from $4.68B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management deployed $226M of net new capital in Q3 2022, opening 18 new positions and adding to 54 existing holdings. Its largest new stake was DoubleVerify: 1,847,144 shares worth $50.5M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 35% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Cogent Biosciences, an estimated $30.6M trimmed.

  • Eventide Asset Management's largest Q3 2022 buy was DoubleVerify: 1,847,144 shares worth $50.5M.
  • Eventide Asset Management added most to Doximity in Q3 2022, an estimated $69.6M increase.
  • Eventide Asset Management's biggest Q3 2022 reduction was Cogent Biosciences, cutting an estimated $30.6M.
  • Eventide Asset Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022, selling an estimated $165M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $5.08B portfolio in Q3 2022.
  • Eventide Asset Management opened 18 new positions and closed 16 in Q3 2022.
  • Eventide Asset Management's portfolio value rose 8.7% quarter-over-quarter to $5.08B.

Based on Eventide Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.